Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Open in API
Filings indexed 1,720 across all filing types
Latest filing 2021-01-27 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-01-27 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a supply agreement with the U.S. Government for a pharmaceutical product. It includes detailed terms of the agreement, payment amounts, and obligations. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or any other report type. The document is a regulatory filing announcing a significant contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is 8074 characters, which is sufficient to contain substantive information, not just a brief announcement or a certification. Hence, the confidence is high.
2021-01-15 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Regeneron Pharmaceuticals, Inc. It reports on a corporate update given at the 39th Annual J.P. Morgan Healthcare Conference, including preliminary unaudited sales figures for 2020. The document includes a presentation as an exhibit but does not contain full financial statements or detailed financial analysis itself. The content is primarily an announcement of recent financial results and corporate updates rather than a full earnings release or annual/interim report. Given the nature of the Form 8-K and the content focusing on results of operations and financial condition, this fits best under the category of Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights. The document length (7573 characters) and content support this classification rather than a full interim report or annual report.
2021-01-11 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-05 English
PRIMARY DOCUMENT
Director's Dealing
2021-01-05 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.